F. HOFFMANN-LA ROCHE AG - Switzerland 

Ranking results:

Past rankings:

2020
Criterium:Position:
Overall Score:> 1000
Total Number of Projects:900-1000
2019
Criterium:Position:
Overall Score:500-600
Total Project Funding per Partner:> 1000
Total Number of Projects:400-500
2018
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:700-800
Networking Rank (Reputation):> 1000
2016
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2014
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:700-800
Total Project Funding per Partner:700-800
Total Number of Projects:68
Total Project Funding:700-800
Networking Rank (Reputation):700-800
Networking Rank (Reputation):700-800
Partner Constancy:46
Project Leadership Index:75
Diversity Index:41

Ranking timeline:

Project Participation Performance(2012-01-01 - 2021-12-31 ):

Total Project Funding:

Funding per Partner:

Projects:

Leadership:

Total number of projects: 41
As coordinator: 0
As participant: 41
Sole participant: 0
Coordinator / Participant Ratio: 0*

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2021 0 64.124.219 468.794 6
2020 0 32.597.381 0 4
2019 0 108.830.360 421.103 8
2018 0 130.275.644 0 4
2017 0 43.440.356 0 5
2016 0 64.482.031 0 7
2015 0 5.972.496 0 1
2014 0 5.998.346 124.247 1
2013 0 15.918.137 762.895 2
2012 0 17.316.160 201.181 3

Networking:

Partners:

Institution:Projects [No]:
NOVARTIS PHARMA21
JANSSEN PHARMACEUTICA NV18
PFIZER LIMITED18
ELI LILLY AND COMPANY LIMITED12
SANOFIAVENTIS12
BAYER10
UNIVERSITY COLLEGE LONDON10
UCB BIOPHARMA9
CHARITE UNIVERSITAETSMEDIZIN BERLIN8
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM8
ABBVIE INC7
ASTRAZENECA7
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG7
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT7
KATHOLIEKE UNIVERSITEIT LEUVEN7
MERCK SHARP & DOHME CORP7
STICHTING KATHOLIEKE UNIVERSITEIT7
TAKEDA DEVELOPMENT CENTRE EUROPE7
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V6
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE6
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN6
TAKEDA PHARMACEUTICALS INTERNATIONAL6
UPPSALA UNIVERSITET6
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE5
KAROLINSKA INSTITUTE5
KING'S COLLEGE LONDON5
NOVO NORDISK5
SANOFIAVENTIS RECHERCHE & DEVELOPPEMENT5
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL5
THE UNIVERSITY OF EDINBURGH5
UNIVERSITAIR MEDISCH CENTRUM UTRECHT5
UNIVERSITEIT MAASTRICHT5
UNIVERSITY OF NEWCASTLE UPON TYNE5
BAYER AKTIENGESELLSCHAFT4
EUROPEAN CANCER PATIENT COALITION4
FORUM DES PATIENTS EUROPEENS4
GOETEBORGS UNIVERSITET4
H LUNDBECK AS4
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER IRIS4
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN4
RIJKSUNIVERSITEIT GRONINGEN4
SERVICIO MADRILENO DE SALUD4
STICHTING VUMC4
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD4
UNIVERSITEIT GENT4
UNIVERSITY OF CAMBRIDGE4
ACADEMISCH ZIEKENHUIS LEIDEN3
ALZHEIMER EUROPE3
ARTTIC3
ASTRAZENECA AB3
COMMISSARIAT A L'ENERGIE ATOMIQUE3
EBERHARD KARLS UNIVERSITAET TUEBINGEN3
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK3
ELI LILLY AND COMPANY3
EUROPEAN MOLECULAR BIOLOGY LABORATORY3
EURORDIS EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION3
FUNDACIO SANT JOAN DE DEU3
INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE3
INSTITUT DE RECHERCHES SERVIER3
INSTITUT PASTEUR3
LUND UNIVERSITY3
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV3
MEDIZINISCHE HOCHSCHULE HANNOVER3
MEDIZINISCHE UNIVERSITAET WIEN3
MEDIZINISCHE UNIVERSITAT INNSBRUCK3
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE3
ORION OYJ3
OSPEDALE PEDIATRICO BAMBINO GESU3
QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON3
REGION HOVEDSTADEN3
STICHTING BURO ECNP3
STICHTING VU3
SYNAPTOLOGICS BV3
TEAM IT RESEARCH SL3
THE EUROPEAN INSTITUTE FOR INNOVATION THROUGH HEALTH DATA3
THE PROVOST FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN HEREINAFTER TRINITY COLLEGE DUBLIN3
THE UNIVERSITY OF LIVERPOOL3
TTOPSTART BV3
UNIVERSITAET BERN3
UNIVERSITAETSMEDIZIN GOETTINGEN GEORGAUGUSTUNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS3
UNIVERSITAT WIEN3
UNIVERSITATSKLINIKUM BONN3
UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY OF IRELAND CORK3
UNIVERSITY OF GLASGOW3
ACADEMISCH ZIEKENHUIS GRONINGEN2
AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN2
AMGEN2
AMGEN LIMITED2
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS2
BIOGEN IDEC LIMITED2
BIOSCI CONSULTING BVBA2
CENTRE DE REGULACIO GENOMICA2
CERTARA UK LIMITED2
CHARLES UNIVERSITY PRAGUE2
CONCENTRIS RESEARCH MANAGEMENT2
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS2
COVANCE LABORATORIES2
EMPIRICA GESELLSCHAFT FUR KOMMUNIKATIONS UND TECHNOLOGIEFORSCHUNG MBH2
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE2
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE2

Constancy:

Total number of partners: 995
Partner loyalty:
Frequent Partner: (> 2 projects): 428
Rare Partner: 567
Frequent / Rare Partner Ratio: 0.75

Project overview:

Start dateProjectacronymrolefundingpartners
2021-10-01Optimal treatment for patients with solid tumours in Europe through Artificial intelligence OPTIMAparticipant10.459.99737
2021-10-01Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies SCREEN4CAREparticipant11.938.56935
2021-07-01Real World Handling of Protein Drugs - Exploration, Evaluation and Education RealHOPEparticipant3.139.98425
2021-02-01Central Repository for Digital Pathology BIGPICTUREparticipant32.319.82548
2021-01-01A fully integrated, animal-free, end-to-end modelling approach to oral drug product development InPharmaparticipant3.475.40211
2021-01-01Drug Absorption in Geriatric Patients and Older People: a training network innovating drug development for the advanced age population AGePOPparticipant2.790.4436
2020-11-01Gravitate–Health: Empowering and Equipping Europeans with health information for Active Personal Health Management and Adherence to Treatment Gravitate-Healthparticipant9.280.00040
2020-10-01H2O Health Outcomes Observatory H2Oparticipant10.476.68723
2020-09-01Prioritisation and Risk Evaluation of Medicines in the EnviRonment PREMIERparticipant4.550.00025
2020-01-01PharmaLedger PharmaLedgerparticipant8.290.69429
2019-12-01Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies imSAVARparticipant10.999.31628
2019-11-01Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis MIRIADEparticipant4.015.37611
2019-11-01Virtual IoT Maintenance System VIMSparticipant2.345.8304
2019-11-01Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases IDEA-FASTparticipant20.997.52347
2019-10-01Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies Immune-Imageparticipant15.000.00023
2019-09-01Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions 3TRparticipant40.273.19270
2019-03-01Efficiently Networking European Neurodegeneration Research NEURONETparticipant1.199.12510
2019-02-01Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease TransBioLineparticipant13.999.99829
2018-10-01European Training Network to Diagnose, Understand and Treat Stargardt Disease, a Frequent Inherited Blinding Disorder StarTparticipant3.776.71415
2018-06-01Autism Innovative Medicine Studies – 2 – Trials AIMS-2-TRIALSparticipant54.999.99948
2018-05-01conect4children (COllaborative Network for European Clinical Trials For Children) c4cparticipant67.000.00047
2018-03-01Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. PARADIGMparticipant4.498.93135
2017-10-01European Quality In Preclinical Data EQIPDparticipant4.495.52330
2017-09-01Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076 MACUSTARparticipant8.025.00013
2017-09-01Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management eTRANSAFEparticipant20.000.00027
2017-02-01Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 DO-ITparticipant3.549.83336
2017-01-01ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064 ITCC-P4participant7.370.00021
2016-11-01Inflammation and AD: modulating microglia function focussing on TREM2 and CD33 - Sofia ref.: 115976 PHAGOparticipant8.838.00020
2016-11-01Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020 ROADMAPparticipant3.998.25026
2016-10-01Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 PREFERparticipant6.000.00033
2016-04-01Psychiatric Ratings using Intermediate Stratified Markers - Sofia ref.: 115916 PRISMparticipant8.080.00023
2016-03-01FRAGments training NETwork FRAGNETparticipant3.842.48213
2016-01-01Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders COSYNparticipant5.925.00014
2016-01-01An Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century EU-ToxRiskparticipant27.798.29941
2015-05-01Exploring the combined role of genetic and non-genetic factors for developing Age-Related Macular Degeneration: A systems level analysis of disease subgroups, risk factors, and pathways EYE-RISKparticipant5.972.49612
2014-02-01Translating neuroimaging findings from research into clinical practice PSYSCANparticipant5.998.34615
2013-10-01Hepatic and Cardiac Toxicity Systems modelling HECATOSparticipant11.999.99914
2013-10-01Deciphering inter- and intracellular signalling in schizophrenia IN-SENSparticipant3.918.13813
2012-05-01New Oral Nanomedicines: Transporting Therapeutic Macromolecules across the Intestinal Barrier TRANS-INTparticipant8.000.00017
2012-02-01Scalable, Standard based Interoperability Framework for Sustainable Pro-active Post Market Safety Studies SALUSparticipant3.325.96510
2012-02-01Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer RESPONSIFYparticipant5.990.19512